Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 59 for “"nilotinib"”.

  1. Nilotinib efflux and resistance development: the effects of combination and concomitant therapies on the transport and efficacy of Nilotinib.

    … (TKIs), such as imatinib, and more recently nilotinib and dasatinib, act by specifically binding to the Bcr-Abl kinase domain. The advent of TKIs resulted in significantly improved treatment outcomes for the majority of patients with CML. However, the focus is now customised treatment regimes …

    adelaide Repository record for Nilotinib efflux and resistance development: the effects of combination and concomitant therapies on the transport and efficacy of Nilotinib. (opens in a new tab)

  2. In vitro Untersuchungen von Therapiekombinationen mit Chemotherapeutika und dem Tyrosinkinase Inhibitor Nilotinib am Ovarialkarzinom

    … und dem Tyrosinkinase Inhibitor Nilotinib am Ovarialkarzinom Hierzu wurden die Methoden Immunhistochemischer Rezeptornachweis, Proliferations-assays, TUNEL-assays und Migrations-assays verwendet

    cau-kiel Repository record for In vitro Untersuchungen von Therapiekombinationen mit Chemotherapeutika und dem Tyrosinkinase Inhibitor Nilotinib am Ovarialkarzinom (opens in a new tab)

  3. Mechanismen der BCR/ABL-unabhängigen Resistenz gegenüber Imatinib und Nilotinib in der chronisch myeloischen Leukämie

    … Mechanismen der Imatinib (IM)- und Nilotinib-Resistenz zu untersuchen. In der Analyse der Rolle des Arzneistofftransporters ABCG2 sowie dessen posttranskriptioneller Regulation zeigte sich, dass die ABCG2-Expression und Funktion durch microRNA-212 negativ beeinflusst wird und deren …

    cau-kiel Repository record for Mechanismen der BCR/ABL-unabhängigen Resistenz gegenüber Imatinib und Nilotinib in der chronisch myeloischen Leukämie (opens in a new tab)

  4. Nilotinib-Mediated Reprogramming Of Bone Marrow Macrophages Alters Hematopoietic Stem Cell Fate In Chronic Myeloid Leukemia

    … within the niche to promote LSC development and nilotinib will reprogram macrophages to selectively support non-leukemic stem cells. To study this, we generated bone marrow chimeras by co-transplanting marrow cells from BCR::ABL1 transgenic mice and non-leukemic mice in a 1:1 ratio into …

    uab Repository record for Nilotinib-Mediated Reprogramming Of Bone Marrow Macrophages Alters Hematopoietic Stem Cell Fate In Chronic Myeloid Leukemia (opens in a new tab)

  5. Combination therapeutics of Nilotinib and radiation in Acute Lymphoblastic Leukemia as an effective method against drug resistance

    … combined effect of the tyrosine kinase inhibitor nilotinib and ionizing radiation on acute lymphoblastic leukemia cells. We develop a mathematical model for the cell response to this combined therapy. This mathematical model is parameterized via cell viability experiments conducted at a variety of …

    umn Repository record for Combination therapeutics of Nilotinib and radiation in Acute Lymphoblastic Leukemia as an effective method against drug resistance (opens in a new tab)

  6. Factors which impact on the response of CML patients to ABL kinase inhibitor therapy: a study of imatinib and nilotinib.

    … could be largely overcome. In contrast, Nilotinib, a more potent second generation tyrosine kinase inhibitor, is not dependent on OCT-1 for influx, making it a possible treatment choice for patients with low OCT-1 Activity. Both imatinib and nilotinib interact with the efflux transporters …

    adelaide Repository record for Factors which impact on the response of CML patients to ABL kinase inhibitor therapy: a study of imatinib and nilotinib. (opens in a new tab)

  7. Epigenetische Veränderungen in der Entwicklung von Chemoresistenzen in der Chronisch Myeloischen Leukämie

    … und der microRNA-212 in der Imatinib- und Nilotinib-Resistenz nachzuvollziehen und insbesondere die DNA-Methylierung als wichtigen epigenetischen Einfluss zu untersuchen. Die Analysen zur Imatinib-Resistenz zeigten eine differentielle Expression von ABCG2, ZFP36L2 und der miR-212 und lassen …

    cau-kiel Repository record for Epigenetische Veränderungen in der Entwicklung von Chemoresistenzen in der Chronisch Myeloischen Leukämie (opens in a new tab)

  8. Αλληλεπίδραση αιμοπεταλίων με καρκινικά κύτταρα: ρόλος στις θρομβωτικές επιπλοκές του καρκίνου και την καρκινογένεση

    … cells, and finally to present new synthetic Nilotinib analogues that express strong antitumor activity. Methods: In this context, twelve new Nilotinib analogues, a BCR-ABL tyrosine kinase inhibitor used to treat chronic myelogenous leukemia, have been designed and synthesized by the Organic …

    greece Repository record for Αλληλεπίδραση αιμοπεταλίων με καρκινικά κύτταρα: ρόλος στις θρομβωτικές επιπλοκές του καρκίνου και την καρκινογένεση (opens in a new tab)

  9. Disease modifying therapy for multiple system atrophy – Parkinsonian Type

    … (Deferiprone) and tyrosine kinase inhibitors (Nilotinib.) METHODS: The proposed study is a multicenter, double blind, randomized control study of Nilotinib and Deferiprone for the treatment of MSA-P. There will be two treatment arms; Nilotinib and a placebo group vs. Nilotinib and Deferiprone. …

    bu Repository record for Disease modifying therapy for multiple system atrophy – Parkinsonian Type (opens in a new tab)

  10. How point mutations confer resistance in BCR-ABL: a computational study

    … kinase and resulting imatinib-resistance. Nilotinib is one of several second generation BCR-Abl tyrosine kinase inhibitors developed to treat imatinib-resistant CML. Nilotinib inhibits the majority of imatinib-resistant mutations, however mutations that are resistant to both imatinib and …

    soton Download PDF for How point mutations confer resistance in BCR-ABL: a computational study (opens in a new tab)

  11. B cell leukemia elicits a suppressive Tr1-CD4+ T cell response that can be reprogrammed with PDL1-blockade.

    … therapy via the tyrosine kinase inhibitor nilotinib prevented leukemia relapse and improved survival. Depletion of CD4+ T cells abrogated the efficacy of the combination therapy, pointing to a key role for CD4s in preventing leukemia relapse. Although inhibitory receptor-expressing (IRhi) T …

    umn Repository record for B cell leukemia elicits a suppressive Tr1-CD4+ T cell response that can be reprogrammed with PDL1-blockade. (opens in a new tab)

  12. Development of Combination Therapies of Pazopanib Through a PK/PD Approach

    … accumulation of pazopanib in Caco-2 cells. Nilotinib can function as an effective efflux transporter inhibitor to reverse the efflux and increase the intracellular accumulation of pazopanib in Caco-2 cells. Concentration-dependent studies showed that nilotinib inhibited the efflux of …

    houston Repository record for Development of Combination Therapies of Pazopanib Through a PK/PD Approach (opens in a new tab)

  13. Long-term adherence and outcomes of oral Tyrosine Kinase Inhibitors for the treatment of CML in the US VHA medical system

    … filled at least one prescription for imatinib, nilotinib, or dasatinib from 10/1/2001 through 9/30/2010 were included in this study. Adherence was ascertained for 2,873 patients by calculating the Medication Possession Ratio (MPR) using administrative refill data. A manual chart review of 683 …

    texas Repository record for Long-term adherence and outcomes of oral Tyrosine Kinase Inhibitors for the treatment of CML in the US VHA medical system (opens in a new tab)

  14. Investigating the effects of ABL kinase inhibitors on the signalling and function of normal leukocytes and leukemic cells.

    … currently approved second generation inhibitors nilotinib and dasatinib are respectively around 20 and 300 times more potent at inhibiting ABL than imatinib. While imatinib blocks ABL kinase activity, it also inhibits several other kinases including LCK, a Src-family kinase involved in T-cell …

    adelaide Repository record for Investigating the effects of ABL kinase inhibitors on the signalling and function of normal leukocytes and leukemic cells. (opens in a new tab)

  15. Evaluation of anti-proliferative and pro-apoptotic effects of tyrosine kinase inhibitors on CML-CD34+ cells.

    … tyrosine kinase inhibitors (TKI), dasatinib, nilotinib and bosutinib. This research elucidates the dasatinib cellular transport pathways and its role in mediating dasatinib resistance. It also assesses dynamics of Bcr-Abl kinase inhibition and apoptosis in CML lines and CML-CD34+ progenitors. …

    adelaide Repository record for Evaluation of anti-proliferative and pro-apoptotic effects of tyrosine kinase inhibitors on CML-CD34+ cells. (opens in a new tab)

  16. Expression and function of drug transporters in primitive CML cells

    … that at therapeutic concentrations (5μM) IM and nilotinib both inhibited ABCG2 and MDR1 and nilotinib also inhibited MRP1. Neither drug was a substrate for any of the transporters. In contrast, dasatinib was shown to be a substrate for ABCG2 and MRP1, but had no effect on MDR1. Therefore activity …

    glasgow Download PDF for Expression and function of drug transporters in primitive CML cells (opens in a new tab)

  17. The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia.

    … in the presence of imatinib, dasatinib and nilotinib, K562-T315I cells proliferate and survive better than in the absence of a TKI. This is due to hyperactivation of the MAPK pathway whereas signalling of other pathways, JAK/STAT5 and PI3K/Akt are not increased. This phenomenon was …

    adelaide Repository record for The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia. (opens in a new tab)

Page 1 of 3